Company: SINT
Filing Date: 2025-05-15
Form Type: 10-Q
Source: 0001641172-25-010496
Chunk: 57

Company: Sintx Technologies, Inc.
Filing Date: 2025-05-15
Form: 10-Q
Item: Item 4
Chunk 57
---
This Report includes the certifications of our Chief
Executive Officer and Principal Financial Officer required by Rule 13a-14 of the Securities Exchange Act of 1934 (the “Exchange
Act”). See Exhibits 31.1 and 31.2. This Item 4 includes information concerning the controls and control evaluations referred to
in those certifications.

Evaluation of Disclosure Controls and Procedures

We maintain disclosure controls and procedures, as
such term is defined in Rules 13a-15(e) and 15d-15(e) of the Securities Exchange Act of 1934 (the “Exchange Act”), that are
designed to ensure that information required to be disclosed in the reports filed or submitted under the Exchange Act, is recorded, processed,
summarized, and reported within the time periods specified by the Commission’s rules and forms. Disclosure controls and procedures
include controls and procedures designed to ensure that information required to be disclosed in our reports filed or submitted under the
Exchange Act are properly recorded, processed, summarized and reported within the time periods required by the Commission’s rules
and forms.

We carried out an evaluation, under the supervision
and with the participation of our management, including our Chief Executive Officer (principal executive officer and principal financial
officer), of the effectiveness of the design and operation of these disclosure controls and procedures, as such term is defined in Exchange
Act Rule 13a-15(e), as of March 31, 2025. Based on this evaluation, the Chief Executive Officer concluded that our disclosure controls
and procedures were effective as of March 31, 2025, the end of the period covered by this Quarterly Report on Form 10-Q.

There were no changes in our internal
control over financial reporting that occurred during the first quarter of 2025 that have materially affected, or are reasonably likely
to materially affect, our internal control over financial reporting.

PART II

ITEM 1. LEGAL PROCEEDINGS

We are not aware of any pending or threatened legal
proceeding against us that could have a material adverse effect on our business, operating results or financial condition. The medical
device industry is characterized by frequent claims and litigation, including claims regarding patent and other intellectual property
rights as well as improper hiring practices. As a result, we may be involved in various legal proceedings from time to time.

Item 1A.
Risk Factors

Information regarding risk factors appears in Item
1A of our Annual Report on Form 10-K for the year ended December